// App-Quantinova.ai

e14041 : Integrated use of tumor AI volumetrics and advanced MRI to assess early response to Temferon in a phase 2 GBM trial: A novel paradigm.

Researchers

Presenter

  • Sotirios Bisdas

Principal Investigators

  • Diana Roettger

  • Valeria Cuccarini

  • Bernhard Gentner

  • Marica Eoli

  • Luigi Naldini

  • Fabio Ciceri

  • Gaetano Finocchiaro

  • Carlo Russo

  • Maria Grazia Bruzzone

Medical Centers

  • Image Analysis, London, United Kingdom

  • Neuropathology Unit, Fondazione IRCCS Istituto Neurologico C Besta, Milano, Italy

  • San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), San Raffaele Scientific Institute, Milan, Italy

  • Neuropathology Unit, Fondazione IRCCS Istituto Neurologico C Besta, Milano, Italy

  • San Raffaele Telethon Institute for Gene Therapy and Vita-Salute University, Milano, Italy

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

  • Genenta Science, Milan, Italy

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • 3β-hydroxysterol Δ24-reductase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03866109

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved